Our data show that the BMP pathway, which is antiproliferative, is selected for inactivation preferentially in k-ras mutant tumours in NSCLC, likely as a direct means of potentiating progrowth signalling. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.